A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and s... - PubMed - NCBI
2018 Mar 7. pii: S0022-5347(18)42488-3. doi: 10.1016/j.juro.2018.03.004. [Epub ahead of print]
A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and systematic prostate biopsy.
, Said J2
, Shindel AW3
, Khoshnoodi P4
, Felker ER4
, Sisk AE Jr.2
, Grogan T5
, McCullough D3
, Bennett J3
, Bailey H3
, Lawrence HJ3
, Elashoff DA5
, Marks LS1
, Raman SS6
, Febbo PG3
, Reiter RE7
Multiparametric MRI (mpMRI) and biopsy-based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ (GPS) assay are increasingly used to improve risk stratification in men with clinically localized prostate cancer (PCa). The GPS assay was previously shown to be a significant independent predictor of adverse pathology (AP) at radical prostatectomy (RP) in men diagnosed with systematic biopsies only. We therefore investigated the ability of GPS to predict AP in the setting of MRI-guided prostate biopsy.
MATERIAL AND METHODS:
We identified men diagnosed with NCCN very low/low/intermediate-risk PCa who underwent simultaneous mpMRI fusion-targeted and systematic prostate biopsy with subsequent RP within 6 months. GPS testing was performed on biopsy tissue of the highest Gleason score (GS). The primary outcome was AP (GS≥4+3 and/or pT3+ at RP). Independent predictors of AP were determined using a multivariable model to adjust for clinical parameters.
134 men were eligible for primary analysis. In univariable analysis, UCLA MRI score, GPS results and biopsy GS were significant predictors of AP. After multivariable adjustment, GPS values remained a significant predictor of AP (OR for GPS per 20 units 3.28, 95%CI 1.74-6.62, p<0.001). A wide and overlapping distribution of GPS results were seen across PI-RADSv2 scores.
The GPS result is an independent predictor of AP in patients who were diagnosed with very low/low/intermediate-risk PCa in the setting of mpMRI-fusion prostate biopsy. This assay can be useful as an independent or adjunct technology to mpMRI for individualizing risk stratification in low and intermediate risk PCa.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
GPS; Genomic Prostate Score™; MRI guided prostate biopsy; Oncotype DX(®); multiparametric MRI
No hay comentarios:
Publicar un comentario